• Policy
• Awareness of Korean pharmaceuticals, ranked 7th out of 13
• by Lee, Hye-Kyung Jun 16, 2023 05:55am

• Policy
• RMP evaluation cycle Up to 3 yrs What items can be changed?
• by Lee, Hye-Kyung Jun 16, 2023 05:55am

• Policy
• Why Vyndamax and Tabrecta’s reimb were unable to pass DREC
• by Lee, Tak-Sun Jun 15, 2023 05:38am

• Policy
• Handok's Imported Monjuvi Licensed
• by Lee, Hye-Kyung Jun 13, 2023 07:39pm

• Policy
• When will the innovative generic price system be improved?
• by Lee, Tak-Sun Jun 12, 2023 05:42am

• Policy
• Adtralza is about to be approved in Korea
• by Lee, Hye-Kyung Jun 9, 2023 05:35am

• Policy
• Voluntary price reduction of Diacomit/Olpadine up to↓40%
• by Lee, Hye-Kyung Jun 5, 2023 05:37am

• Policy
• Evrysdi, a tx for Roche's spinal muscular dystrophy, passed
• by Lee, Hye-Kyung Jun 5, 2023 05:37am

• Policy
• Non-face-to-face demonstration will be alternative relief ?
• by Lee, Jeong-Hwan Jun 5, 2023 05:37am

• Policy
• The method of revaluation of wages that Godex has changed
• by Lee, Tak-Sun Jun 5, 2023 05:36am